ABCD1 marker validated

Pathologists use immunohistochemistry like a color-coded label on tissue slides, and a new multi-institutional study says ABCD1 can sharply improve recognition of pancreatic solid pseudopapillary neoplasm on small biopsies. (sciencedirect.com) Solid pseudopapillary neoplasm, or SPN, is a rare pancreatic tumor that accounts for about 1% to 3% of pancreatic tumors and occurs predominantly in young women. It is usually considered low grade, with 5-year survival above 95% after complete resection. (pathologyoutlines.com) (pathsocjournals.onlinelibrary.wiley.com) The diagnostic problem comes on limited samples. Reviews of SPN note that cytology and core biopsy material can mimic pancreatic neuroendocrine tumor and other pancreatic neoplasms, especially when the classic architecture is missing. (ncbi.nlm.nih.gov) (mdpi.com) ABCD1 is a protein associated with the peroxisome, a cell compartment that helps process fats. In a 2024 study, investigators reported that SPNs showed increased peroxisomes and marked upregulation of ABCD1 compared with normal pancreas and pancreatic neuroendocrine tumors. (ncbi.nlm.nih.gov) (uniprot.org) That earlier paper tested 127 SPN samples, including 111 primary and 16 metastatic tumors, against 108 neuroendocrine tumors and several other pancreatic lesions. The authors concluded that ABCD1 immunostaining had potential utility as a diagnostic marker for SPN in routine pathology practice. (pubmed.ncbi.nlm.nih.gov) The new Human Pathology-linked report shifts the question from resection specimens to biopsy material. Its title describes ABCD1 as “a highly sensitive diagnostic marker” for SPN in biopsy samples and says the work was done across multiple institutions. (sciencedirect.com) That matters because treatment decisions are often made before surgery, using endoscopic ultrasound-guided fine-needle aspiration, core biopsy, or cytology cell blocks. A cleaner distinction from neuroendocrine tumor can help avoid the wrong diagnostic label on a rare pancreatic mass. (apc.amegroups.org) (colab.ws) SPN already has a familiar immunostain pattern, including nuclear beta-catenin, but recent reviews say the field still lacks fully specific biomarkers for recurrent, metastatic, or otherwise difficult cases. The same reviews describe newer markers, including ABCD1, as part of a broader push to tighten diagnosis when morphology alone is not enough. (pathologyoutlines.com) (pathsocjournals.onlinelibrary.wiley.com) The immediate next step is less about discovering SPN than about making the call faster and with more confidence on scant tissue. For a tumor that is rare, usually resectable, and often seen in younger patients, that is where a marker earns its place. (sciencedirect.com) (pathsocjournals.onlinelibrary.wiley.com)